S&P 500   3,783.28
DOW   30,273.87
QQQ   281.98
5 Tips I Wish I Knew Before Starting My Business
Reclusive trader scores 20 years of winning trades. Learn how. (Ad)pixel
Live Updates: Russia-Ukraine War
Too Soon: 3 Reasons to Wait on DocuSign Stock
Reclusive trader scores 20 years of winning trades. Learn how. (Ad)pixel
WTO predicts trade growth to slow next year amid crises
OPEC+ makes big oil cut to boost prices; pump costs may rise
Reclusive trader scores 20 years of winning trades. Learn how. (Ad)pixel
Stocks slump as Wall Street’s big rally fades, yields rise
Rite-Aid Sings a Familiar Tune That Investors Don’t Want to Hear
S&P 500   3,783.28
DOW   30,273.87
QQQ   281.98
5 Tips I Wish I Knew Before Starting My Business
Reclusive trader scores 20 years of winning trades. Learn how. (Ad)pixel
Live Updates: Russia-Ukraine War
Too Soon: 3 Reasons to Wait on DocuSign Stock
Reclusive trader scores 20 years of winning trades. Learn how. (Ad)pixel
WTO predicts trade growth to slow next year amid crises
OPEC+ makes big oil cut to boost prices; pump costs may rise
Reclusive trader scores 20 years of winning trades. Learn how. (Ad)pixel
Stocks slump as Wall Street’s big rally fades, yields rise
Rite-Aid Sings a Familiar Tune That Investors Don’t Want to Hear
S&P 500   3,783.28
DOW   30,273.87
QQQ   281.98
5 Tips I Wish I Knew Before Starting My Business
Reclusive trader scores 20 years of winning trades. Learn how. (Ad)pixel
Live Updates: Russia-Ukraine War
Too Soon: 3 Reasons to Wait on DocuSign Stock
Reclusive trader scores 20 years of winning trades. Learn how. (Ad)pixel
WTO predicts trade growth to slow next year amid crises
OPEC+ makes big oil cut to boost prices; pump costs may rise
Reclusive trader scores 20 years of winning trades. Learn how. (Ad)pixel
Stocks slump as Wall Street’s big rally fades, yields rise
Rite-Aid Sings a Familiar Tune That Investors Don’t Want to Hear
S&P 500   3,783.28
DOW   30,273.87
QQQ   281.98
5 Tips I Wish I Knew Before Starting My Business
Reclusive trader scores 20 years of winning trades. Learn how. (Ad)pixel
Live Updates: Russia-Ukraine War
Too Soon: 3 Reasons to Wait on DocuSign Stock
Reclusive trader scores 20 years of winning trades. Learn how. (Ad)pixel
WTO predicts trade growth to slow next year amid crises
OPEC+ makes big oil cut to boost prices; pump costs may rise
Reclusive trader scores 20 years of winning trades. Learn how. (Ad)pixel
Stocks slump as Wall Street’s big rally fades, yields rise
Rite-Aid Sings a Familiar Tune That Investors Don’t Want to Hear
NASDAQ:GLPG

Galapagos - GLPG Stock Forecast, Price & News

$44.22
-1.00 (-2.21%)
(As of 10/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$43.50
$44.38
50-Day Range
$42.27
$55.16
52-Week Range
$41.65
$72.11
Volume
58,737 shs
Average Volume
283,676 shs
Market Capitalization
$2.91 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$62.75

Galapagos MarketRank™ Forecast

Analyst Rating
Hold
2.14 Rating Score
Upside/​Downside
41.9% Upside
$62.75 Price Target
Short Interest
Healthy
0.85% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.42mentions of Galapagos in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($3.23) to ($3.95) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.82 out of 5 stars

Medical Sector

883rd out of 1,072 stocks

Pharmaceutical Preparations Industry

440th out of 534 stocks

GLPG stock logo

About Galapagos (NASDAQ:GLPG) Stock

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Receive GLPG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Galapagos and its competitors with MarketBeat's FREE daily newsletter.

GLPG Stock News Headlines

The Galapagos Is Back In Business - Forbes
Where Galapagos Stands With Analysts
Galapagos to present at upcoming investor conferences
See More Headlines
Receive GLPG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Galapagos and its competitors with MarketBeat's FREE daily newsletter.

GLPG Company Calendar

Last Earnings
8/04/2022
Today
10/05/2022
Next Earnings (Estimated)
11/04/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GLPG
Employees
1,309
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$62.75
High Stock Price Forecast
$70.00
Low Stock Price Forecast
$55.00
Forecasted Upside/Downside
+41.9%
Consensus Rating
Hold
Rating Score (0-4)
2.14
Research Coverage
7 Analysts

Profitability

Net Income
$-122,130,000.00
Pretax Margin
-15.65%

Debt

Sales & Book Value

Annual Sales
$573.66 million
Book Value
$47.71 per share

Miscellaneous

Free Float
63,816,000
Market Cap
$2.91 billion
Optionable
Optionable
Beta
0.45

Key Executives

  • Mr. Bart Filius M.B.A. (Age 52)
    MBA, Pres, COO & Member of Management Board
    Comp: $789.98k
  • Dr. Andre Hoekema Ph.D. (Age 65)
    Chief Bus. Officer & Member of Management Board
    Comp: $556.61k
  • Dr. Walid Abi-Saab (Age 57)
    Chief Medical Officer & Member of Management Board
    Comp: $657.5k
  • Mr. Michele Manto M.B.A.
    Chief Commercial Officer & Member of Management Board
  • Dr. Paulus A. Stoffels M.D. (Age 60)
    Ph.D., CEO, Chairman & Member of Management Board
  • Ms. Elizabeth Goodwin
    VP of Investor Relations
  • Ms. Sofie Van Gijsel
    Head of Investor Relations
  • Marieke Vermeersch
    Head of Corp. Communication
  • John Montana
    Managing Director of Argenta
  • Ms. Chantal Tasset
    Head of Devel.













GLPG Stock - Frequently Asked Questions

Should I buy or sell Galapagos stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Galapagos in the last year. There are currently 1 sell rating, 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" GLPG shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GLPG, but not buy additional shares or sell existing shares.
View GLPG analyst ratings
or view top-rated stocks.

What is Galapagos' stock price forecast for 2022?

7 analysts have issued twelve-month price targets for Galapagos' stock. Their GLPG share price forecasts range from $55.00 to $70.00. On average, they anticipate the company's share price to reach $62.75 in the next year. This suggests a possible upside of 41.9% from the stock's current price.
View analysts price targets for GLPG
or view top-rated stocks among Wall Street analysts.

How have GLPG shares performed in 2022?

Galapagos' stock was trading at $55.13 at the beginning of the year. Since then, GLPG stock has decreased by 19.8% and is now trading at $44.22.
View the best growth stocks for 2022 here
.

When is Galapagos' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, November 4th 2022.
View our GLPG earnings forecast
.

How were Galapagos' earnings last quarter?

Galapagos NV (NASDAQ:GLPG) released its earnings results on Thursday, August, 4th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.79) by $0.48. The biotechnology company earned $146.62 million during the quarter, compared to the consensus estimate of $95.44 million. Galapagos had a negative trailing twelve-month return on equity of 3.02% and a negative net margin of 16.90%.

What is Onno van de Stolpe's approval rating as Galapagos' CEO?

6 employees have rated Galapagos Chief Executive Officer Onno van de Stolpe on Glassdoor.com. Onno van de Stolpe has an approval rating of 100% among the company's employees. This puts Onno van de Stolpe in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Galapagos own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Galapagos investors own include Gilead Sciences (GILD), Celyad Oncology (CYAD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), argenx (ARGX), AbbVie (ABBV), Biogen (BIIB), Pharming Group (PHGUF), Trade Desk (TTD) and Collegium Pharmaceutical (COLL).

When did Galapagos IPO?

(GLPG) raised $161 million in an initial public offering (IPO) on Thursday, May 14th 2015. The company issued 3,800,000 shares at $42.43 per share. Morgan Stanley, Credit Suisse and Cowen and Company acted as the underwriters for the IPO and Nomura and Bryan, Garnier were co-managers.

What is Galapagos' stock symbol?

Galapagos trades on the NASDAQ under the ticker symbol "GLPG."

How do I buy shares of Galapagos?

Shares of GLPG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Galapagos' stock price today?

One share of GLPG stock can currently be purchased for approximately $44.22.

How much money does Galapagos make?

Galapagos (NASDAQ:GLPG) has a market capitalization of $2.91 billion and generates $573.66 million in revenue each year.

How many employees does Galapagos have?

The company employs 1,309 workers across the globe.

How can I contact Galapagos?

Galapagos' mailing address is GEN DE WITTELAAN L11 A3, MECHELEN C9, 2800. The official website for the company is www.glpg.com. The biotechnology company can be reached via phone at (321) 534-2900, via email at ir@glpg.com, or via fax at 321-534-2901.

This page (NASDAQ:GLPG) was last updated on 10/6/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.